CD19 and B-cell non-Hodgkin lymphoma: Another clinical trial aimed at determining long-term follow-up of anti-CD19 CAR- T cell therapy has reported the longest durable remission in patients with B cell lymphoma—up to 113 months after treatment—suggesting that anti-CD19 CAR T cells may be curative for B cell lymphoma.447 The success of anti-CD19 CAR-T therapy could be related to the high expression of CD19 in some B cell malignancies and its specificity to the B cell lineage.